NCT06186388 is a NA clinical trial of TEMPO iMOvifa in Glaucoma, sponsored by Cape Fear Eye Institute.

Who is sponsoring NCT06186388?

NCT06186388 is sponsored by Cape Fear Eye Institute.

What drugs are being tested in NCT06186388?

Interventions in NCT06186388: TEMPO iMOvifa.

Is NCT06186388 still recruiting?

NCT06186388 is currently completed. Last updated 26 August 2024.

Last reviewed 2024-08-26 · How we verify

NCT06186388

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glaucoma Screening

Completed NA Last updated 26 August 2024

What this trial tests

NA trial testing TEMPO iMOvifa in Glaucoma in 200 participants. Completed in 15 May 2024.

Timeline

5 December 2023

Primary endpoint
15 May 2024

15 May 2024

Quick facts

Lead sponsor	Cape Fear Eye Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	200
Start date	5 December 2023
Primary completion	15 May 2024
Estimated completion	15 May 2024
Sites	1 location across United States

Drugs / interventions tested

TEMPO iMOvifa

Conditions studied

Glaucoma — all drugs for Glaucoma →

Sponsor

Cape Fear Eye Institute

Who can join

40 and older, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

* The primary objective of this study is to evaluate the diagnostic accuracy of the TEMPO (iMOvifa) visual field perimeter screening test by measuring the sensitivity in a population of eyes with glaucoma and the specificity in a population of normal eyes and to measure repeatability of the screening test. * The secondary objective of this study is to gather and analyze ancillary data to confirm the diagnosis or absence of glaucoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06186388 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cape Fear Eye Institute
Last refreshed: 26 August 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06186388.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing